Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Running

SPACE-MEL SPAtial single-CEll omics research training for MELanoma precision medicine

Coordinator
Katholieke Universiteit Leuven, Belgium
Runs
1 September 2026 to 31 August 2030
Status
Running
EU funding
€4.6m
Total cost
—
Partners
20 organisations in 9 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101311007

What the project is doing

In the project's own words, from its summary on CORDIS.

Spatial technologies are enabling researchers to spatially map cellular heterogeneity and cellular interactions with unprecedented molecular precision, providing insights into the spatial organisation and functional states of cells in complex tissues. Despite their enormous potential, several challenges at experimental and computational level still needs to be solved, a gap hindering their translation into clinics. SPACE-MEL aims to harness the full impact of spatial single-cell omics to advance precision medicine by 1) moving from 2D to 3D analysis, 2) achieving multi-omics technology integration on a single sample for greater accuracy, both in the experimental and computational fields, and 3) creating the expertise to interpret the vast and complex datasets generated and maximise the biological insights obtained using these techniques.

To achieve this, our inter-disciplinary and cross-sectoral network will train 15 doctoral candidates (DCs) in the fields of spatial single-cell imaging technologies, molecular biology, computational biology, pathology and biomarker discovery. Our holistic training programme will equip DCs with both research and transferable skills to navigate spatial biology from beginning to end. With direct training from leading innovators in the spatial biology value chain, SPACE-MEL DCs will graduate as the first generation of scientists with a complete spatial biology background.

The involvement of technology providers and leading companies in the field, as well as close collaboration with the EORTC group will be key to address major scientific and societal challenges and ensure Europe remains at the forefront of innovation in this rapidly advancing field.

Topics

Who is involved

OrganisationCityCountryRole
Katholieke Universiteit LeuvenLeuvenBelgiumCoordinator
Aspect AnalyticsGenkBelgiumParticipant
Biolizard NVGentBelgiumAssociatedpartner
Accelopment Schweiz AGZurichSwitzerlandAssociatedpartner
Lunaphore Technologies SALausanneSwitzerlandAssociatedpartner
Universitat ZurichZurichSwitzerlandParticipant
Intelligent Biodata SLSan SebastianSpainParticipant
Universidad De NavarraPamplonaSpainAssociatedpartner
Sanofi-Aventis Recherche & DeveloppementGentillyFranceAssociatedpartner
Diatech Pharmacogenetics Societa a Responsabilita LimitataJesiItalyAssociatedpartner
Universita Degli Studi Di FirenzeFlorenceItalyParticipant
Universita Degli Studi Di PerugiaPerugiaItalyParticipant
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
Skylinedx B.v.RotterdamNetherlandsAssociatedpartner
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie -Panstwowy Instytut BadawczyWarszawaPolandParticipant
Spotlight Pathology Ltd.WarringtonUnited KingdomAssociatedpartner
The University of ManchesterManchesterUnited KingdomParticipant
Alpenglow Biosciences, Inc.SeattleUnited StatesAssociatedpartner
AtlasXomics, Inc.New HavenUnited StatesAssociatedpartner
Stellaromics, Inc.BostonUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI